Fusion Needs More Money or More Collaboration

Editor’s note: In late October the congressional Office of Technology Assessment issued a report, Starpower The U.S. and the International Quest for Fusion Energy (for a related story, seep. 8). The report, excerpted here, outlines four funding approaches for fusion research over the next few years. The Department of Energy (DOE) manages the U.S. fusion program, and its goal is to evaluate fusion’s technological feasibility— to determine whether or not a fusion reactor can be

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Editor’s note: In late October the congressional Office of Technology Assessment issued a report, Starpower The U.S. and the International Quest for Fusion Energy (for a related story, seep. 8). The report, excerpted here, outlines four funding approaches for fusion research over the next few years.

The Department of Energy (DOE) manages the U.S. fusion program, and its goal is to evaluate fusion’s technological feasibility— to determine whether or not a fusion reactor can be designed and built—early in the 21st century. A positive evaluation would enable a decision to be made at that time to construct a prototype commercial reactor. However, this schedule cannot be met under existing U.S. fusion budgets. The DOE plan requires either that U.S. budget be increased substantially or that the world fusion programs collaborate much more closely on fusion research.

Research aimed at developing fusion as an energy source has been vigorously pursued since ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies